Lumakras (sotorasib) — United Healthcare
central nervous system cancers (brain metastases)
Initial criteria
- Diagnosis of brain metastases
- Metastases from KRAS G12C-mutated positive non-small cell lung cancer
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lumakras therapy
Approval duration
12 months